Investigational drug · Phase 3
OBR
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for HIV-1-infection.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
35
Any phase or sponsor naming "OBR"
First trial start
2019
Nov 21, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "OBR", any sponsor or status.
Conditions studied
As listed on its trial records.
- HIV-1-infection
Approved drugs for the same conditions: HIV · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "OBR" as an intervention, largest first.
Tibotec Pharmaceuticals, IrelandIndustry
NCT00254046 · 616 participants · Start Nov 2005 · Primary completion Feb 2007
Drug: TMC125; Placebo · For: HIV
Sites: Little Rock, Arkansas; Beverly Hills, California; Los Angeles, California · 55 sites in all
Tibotec Pharmaceuticals, IrelandIndustry
NCT00255099 · 593 participants · Start Dec 2005 · Primary completion Jan 2007
Drug: TMC125; Placebo · For: HIV
- Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant TuberculosisPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT01424670 · 511 participants · Start Sep 2, 2011 · Primary completion Jul 4, 2016
Drug: Delamanid + OBR; Placebo + OBR · For: Multidrug-resistant Tuberculosis
Sites: Tartu, Estonia; Riga, Latvia; Šiauliai, Lithuania · 17 sites in all
- An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).Pivotal-lookingCompleted
Tibotec Pharmaceuticals, IrelandIndustry
NCT00359021 · 503 participants · Start Jun 2006 · Primary completion Jan 2012
Drug: TMC125 · For: HIV-1
Sites: Phoenix, Arizona; Little Rock, Arkansas; Beverly Hills, California · 72 sites in all
- A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)Pivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT00685360 · 481 participants · Start May 8, 2008 · Primary completion Jun 11, 2010
Drug: Delamanid; Optimized Background Regimen (OBR) and 1 more · For: Tuberculosis, Pulmonary; Tuberculosis, Multidrug Resistant; Extensively Drug-Resistant Tuberculosis
Sites: San Antonio, Texas; Beijing, China; Shanghai, China · 17 sites in all
- Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of ObesityCompleted
Rhythm Pharmaceuticals, Inc.Industry
NCT03013543 · 213 participants · Start Feb 10, 2017 · Primary completion Mar 1, 2022
Drug: Setmelanotide · For: Genetic Obesity; Obesity; Obesity Due to Melanocortin 4 Receptor Deficiency
Sites: Birmingham, Alabama; Chandler, Arizona; Mesa, Arizona · 58 sites in all
- A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683Pivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT02573350 · 213 participants · Start Mar 26, 2009 · Primary completion Oct 27, 2011
Drug: Delamanid; OBR · For: Tuberculosis, Multidrug-Resistant
Sites: Beijing, China; Tallinn, Estonia; Tartu, Estonia · 8 sites in all
- Study of Epetraborole in Patients With Treatment-refractory MAC Lung DiseasePivotal-lookingTerminated
AN2 Therapeutics, IncIndustry
NCT05327803 · 177 participants · Start May 20, 2022 · Primary completion Dec 18, 2024
Drug: Epetraborole; Placebo · For: MAC Lung Disease; Treatment Refractory MAC Lung Disease
Sites: Birmingham, Alabama; Tucson, Arizona; Sacramento, California · 91 sites in all
EpividianIndustry
NCT05495204 · 141 participants · Start Aug 5, 2022 · Primary completion Feb 20, 2023
Drug: Ibalizumab · For: HIV-1-infection
Sites: Durham, North Carolina
- Efficacy and Safety of Levofloxacin for the Treatment of MDR-TBPivotal-lookingCompleted
Boston UniversityAcademic, hospital or other
NCT01918397 · 111 participants · Start Jan 2015 · Primary completion Mar 29, 2022
Drug: Levofloxacin; Optimized background regimen (OBR) · For: Tuberculosis, Multidrug-Resistant
Sites: Lima, Peru; Cape Town, South Africa · 3 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A novel supramolecular assembly constructed from cucurbit[8]uril and tetraphenylethylene derivative for the detection of Fe(CN)63- and picric acid.
Wang T, Tang Y, Fan Y, et al. · Spectrochim Acta A Mol Biomol Spectrosc 2026
- Comparative Evaluation of Propofol, Eugenol and MS-222 in Yellowtail Tetra Astyanax lacustris: Anesthetic Efficacy, Physiological Responses and Recovery Dynamics.
Tavares da Silva BDC, Raspantini LER, Górniak SL · Animals (Basel) 2026
- Twelve-month outcomes after open bleb revision for Preserflo® microshunt bleb failure in refractory glaucoma patients.
Darmon J, Bastelica P, Huard M, et al. · Graefes Arch Clin Exp Ophthalmol 2026
- Comparison of AMSTAR 2 and ROBIS Ratings and Inter-Rater Reliability for Each Scale Based on Systematic Reviews/Meta-Analyses.
Storman M, Storman D, Świerz MJ, et al. · Obes Rev 2026
- Reducing the residual oil body content in soy protein isolate (SPI) through pH regulation and studying the changes in physicochemical, flavor profiles, and processing properties.
Nagassa M, He S, Liu S, et al. · Food Chem 2026
- Au Single-Atom Interlayer Bridge Promotes Cross-Layer Charge Transport and Intrinsic Catalytic Dual-Sites Activation for Efficient CO2 Photoreduction.
Yu Y, Hu J, Chen F, et al. · Angew Chem Int Ed Engl 2026
Also in development for HIV-1-infection
- GS-3242Phase 33 trials
Gilead Sciences · HIV-1-infection, HIV-1 Infection
- LEN FDCPhase 33 trials
Gilead Sciences · HIV-1-infection, HIV-1 Infection
- TAFPhase 33 trials
Gilead Sciences · HIV-1-infection, Chronic Hepatitis B
- TeropavimabTAB, GS-5423Phase 33 trials
Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection
- ZinlirvimabGS-2872, ZABPhase 33 trials
Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection
- TMB-365TMB-380, VRC07523LSPhase 23 trials
TaiMed Biologics Inc. · HIV-1-infection, HIV -1 Infection
- CAP256V2LSPhase 21 trial
Gilead Sciences · HIV-1-infection
- PirmitegravirPhase 21 trial
ST Pharm Co., Ltd. · HIV-1-infection
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Gilead Sciences.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.